---
title: "Stelara (ustekinumab) in plaque psoriasis: Dosing and administration questions"
description: "Dosing and administration questions on Stelara (ustekinumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Treatment combinations, Dosing, and Administration. Questions: Can Stelara be combined with phototherapy or immunosuppressants for psoriasis? What is the Stelara dose for adults with plaque psoriasis? What is the Stelara dose for children with plaque psoriasis? Can patients self-inject Stelara? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/dosing-and-administration"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Stelara (ustekinumab) in plaque psoriasis: Dosing and administration questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Stelara](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf)

Dosing and administration questions that apply to every indication of Stelara are on [Stelara (ustekinumab), all indications: Dosing and administration](https://www.evicenter.com/medical-information/stelara/dosing-and-administration).

## Treatment combinations

<a id="stelara-phototherapy-combination"></a>

### Can Stelara be combined with phototherapy or immunosuppressants for psoriasis?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “In trials in subjects with plaque psoriasis the safety of STELARA in combination with 
> immunosuppressive agents or phototherapy has not been evaluated.”

Source: [STELARA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=6)

## Dosing

<a id="stelara-adult-dose"></a>

### What is the Stelara dose for adults with plaque psoriasis?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “For patients weighing 100 kg or less, the recommended dosage is 45 mg initially 
> and 4 weeks later, followed by 45 mg every 12 weeks.
> •	 For patients weighing more than 100 kg, the recommended dosage is 90 mg 
> initially and 4 weeks later, followed by 90 mg every 12 weeks.
> In subjects weighing more than 100 kg, 45 mg was also shown to be efficacious. 
> However, 90 mg resulted in greater efficacy in these subjects [see Clinical 
> Studies (14.1)].”

Source: [STELARA: Prescribing information, page 2, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=2)

> “Dosing Every 12 Weeks After 2 Starter Doses 
> at Weeks 0 and 4<sup>1</sup>”

Source: [STELARA: STELARA® (ustekinumab) Dosing for Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/dosing/#:~:text=Dosing%20Every%2012%20Weeks%20After,at%20Weeks%200%20and)

<a id="stelara-pediatric-dose"></a>

### What is the Stelara dose for children with plaque psoriasis?

Applies to: Pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “Administer STELARA subcutaneously at Weeks 0 and 4, then every 12 weeks 
> thereafter.
> The recommended dose of STELARA for pediatric patients 6 years of age and 
> older with plaque psoriasis based on body weight is shown below (Table 1).
> Table 1: Recommended Dose of STELARA for Subcutaneous Injection in Pediatric 
> Patients 6 Years of Age and Older With Plaque Psoriasis
> Body Weight of Patient at the Time of Dosing
> Recommended Dose
> less than 60 kg
> 0.75 mg/kg
> 60 kg to 100 kg
> 45 mg
> more than 100 kg
> 90 mg
> For pediatric patients weighing less than 60 kg, the administration volume for the 
> recommended dose (0.75 mg/kg) is shown in Table 2; withdraw the appropriate 
> volume from the vial.”

Source: [STELARA: Prescribing information, page 2, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=2)

Note: Table 2 of the prescribing information lists the injection volume from the 45 mg/0.5 mL vial for each body weight from 15 kg to 59 kg.

## Administration

<a id="stelara-self-injection"></a>

### Can patients self-inject Stelara?

> “STELARA<sup>®</sup>, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who wiII be closely monitored and have regular follow-up. Patients may self-inject with STELARA<sup>®</sup> after physician approval and proper training. Patients should be instructed to follow the directions provided in the Medication Guide.”

Source: [STELARA: STELARA® (ustekinumab) Dosing for Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/dosing/#:~:text=available%20as%2045%20mg%20and,provided%20in%20the%20Medication%20Guide.)

> “STELARA is intended for use under the guidance and supervision of a 
> healthcare provider. STELARA should only be administered to patients who 
> will be closely monitored and have regular follow-up visits with a healthcare 
> provider. The appropriate dose should be determined by a healthcare provider 
> using the patient’s current weight at the time of dosing. In pediatric patients, it 
> is recommended that STELARA be administered by a healthcare provider. If a 
> healthcare provider determines that it is appropriate, a patient may self-inject 
> or a caregiver may inject STELARA after proper training in subcutaneous injection 
> technique. Instruct patients to follow the directions provided in the Instructions 
> for Use [see Instructions for Use].”

Source: [STELARA: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=3)

## Related pages
- [Medical information: Stelara (ustekinumab): Plaque psoriasis](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/specific-populations)
- [Storage and supply](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/storage-and-supply)
